Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Matalan GI:n ruokavalion vaikutukset alkoholittomaan rasvamaksasairauksiin (LGI-NAFLD)

maanantai 13. heinäkuuta 2026 päivittänyt: University of Nottingham

Isoenergeettisen matalan glykeemisen indeksin (GI) ruokavalion vaikutukset maksan rasvan kertymiseen ja suoliston mikrobiston koostumukseen potilailla, joilla on alkoholiton rasvamaksatauti (NAFLD)

A 2 x 2 cross-over dietary intervention trial designed to investigate the effects of low glycemic index (LGI) versus high glycemic index (HGI) diet on hepatic fat accumulation and gut microbiota composition in participants with NAFLD.

Participants will be allocated randomly to a 2-week either high GI (HGI) or low GI (LGI) diet followed by a 4-week wash-out period and then the LGI or HGI diet, opposite to the first 2-weeks (N= 16).

Tutkimuksen yleiskatsaus

Tila

Valmis

Ehdot

Interventio / Hoito

Yksityiskohtainen kuvaus

Following the screening phase and standardisation week, each participant will experience two, 2-week intervention phases, with a 4-week washout period between interventions. Before and after each intervention period they will attend the Imaging Centre (Sir Peter Mansfield Imaging Centre) for MRI scan measurements and then will attend the Biomedical Research Centre for FibroScan, and blood and stool samples collection. During each intervention phase each participant will be required to consume all the food that has been provided, fill in dietary compliance sheets and complete Visual Analogue Scales (VAS) relating to subjective appetite ratings.

Design of the dietary interventions Energy expenditure will be estimated for each participant using the individual's basal metabolic rate calculated from Henry-modified Schofield formula and multiplied by an activity factor based on the IPAQ score physical activity levels. A menu, consisting of meals for 3 days personalised for energy requirement, will be devised (these meals are repeated over 2 weeks) by adjusting a template according to their estimated energy requirement in order to minimise weight change during the intervention phase. The diet consists of normal food closely resembling that described by Bawden et al study. A diet template of 2000 kcal/day with energy proportions distributed as 55% from carbohydrates, 15% from protein and 30% from fat are designed and food quantities will be modified to supply the energy requirements for each participant. Three-day cycle menu plans are designed for each diet (LGI/ HGI). Table 1 shows example template menus for both HGI (a) and LGI (b) diets.

The GI values of commercial food items are generated from that reported by Henry et al, as well as Nutritics software databases (Nutritics). The dietary GI of the menu is calculated from GI proportional contribution to total carbohydrate using the equation: GI=∑(Cfood/Ctotal) × GIfood; where Cfood is the amount of carbohydrate contained in each digested food (g), Ctotal is the total carbohydrate in the meal and is the reported GI of the food. The GL of the diet is calculated based on the dietary GI and the amount of carbohydrate provided (the same in both diets) using the following equation: GL=(GIfood × Cfood)/100; where GI is the GI of each digested food and food is the amount of carbohydrate in the food. Food composition analysis and evaluation were performed using Nutritics software (Nutritics, Dublin, Ireland, 2018).

Participants will be provided with the food at the start of each 2-week diet period and will be clearly instructed on safe food storage and reheating. They will be required to complete dietary compliance sheet on a daily basis. Instructions on dietary compliance will be given at each study period and the dietary compliance records will be reviewed regularly during the intervention to assess their compliance. For the first 1 week prior to the intervention (1-week standardisation), and during the 4-week wash-out period, participants will be asked to avoid eating probiotics, yoghurt and cultured milk drink; if any, to standardise their gut microbiota and avoid any carry-over effects as shown in previous studies.Meal-timing will be standardised among all participants as much as possible during the intervention as well as during the standardisation period.

Opintotyyppi

Interventio

Ilmoittautuminen (Todellinen)

12

Vaihe

  • Ei sovellettavissa

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskelupaikat

  • Yhdistynyt kuningaskunta
    • Nottinghamshire
      • Nottingham, Nottinghamshire, Yhdistynyt kuningaskunta, NG7 2UH
        • NIHR Nottingham Clinical Research Facility Nottingham Digestive Diseases Centre

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

18 vuotta - 65 vuotta (Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria:

  • • Adult males and females aged from 18 to 65 years (balanced number).

    • Detected NAFLD by CAP-FibroScan™ >288dB/m or by MRI-PDFF) > 5% fat of liver weight.
    • Body mass index ≥ 25 kg/m2
    • Have current moderate to high GI diet intake of ≥ 60 (Assessed from a completed 7-day food diary).
    • Abdominal obesity (Waist circumference > 102 cm for males and > 88 cm for females)
    • Able to give informed consent.
    • Able to undergo MRI/S and CAP-FibroScan™.

Exclusion Criteria:

  • • Current smokers and excessive alcohol drinkers (> 14 units/week).

    • Perimenopausal (irregular periods) women.
    • Participants with other liver abnormalities.
    • Participants with history of gastrointestinal surgeries, depression, eating disorders or difficulties.
    • Participants using pharmacologic agents for obesity or NAFLD.
    • Participants with type 1 diabetes.
    • Participants with type 2 diabetes on second line medications (eg GLP-1 analogues, sulfonylureas).
    • Participation in any other trial in the last 3 months.
    • Participants on any special diets (e.g. vegetarians).
    • Intolerance to foods included in the diet plan.

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Muut
  • Jako: Satunnaistettu
  • Inventiomalli: Crossover-tehtävä
  • Naamiointi: Nelinkertaistaa

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: LGI Diet

low glycemic index diet
Muut: low glycemic index diet

• Three-day cycle menu of LGI diet will be designed and supplied to each participant in an amount designed to meet their estimated energy requirements. The percentage energy from protein, fat and carbohydrate will be the same in the two diets. Each diet period of the trial will last for two weeks.

Muut nimet:
  • LGI
Muut: HGI Diet

High glycemic index diet
Muut: High glycemic index diet

Three-day cycle menu of HGI diet will be designed and supplied to each participant in an amount designed to meet their estimated energy requirements. The percentage energy from protein, fat and carbohydrate will be the same in the two diets. Each diet period of the trial will last for two weeks.

Muut nimet:
  • HGI

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Change in Liver Fat Content From Baseline to End of Each 2-Week Dietary Intervention
Aikaikkuna: Baseline and end of each 2-week dietary intervention period

Change in liver fat content (%) from baseline to the end of each 2-week dietary intervention period (LGI diet and HGI diet) in participants with NAFLD. Liver fat content was measured using magnetic resonance spectroscopy. Values represent liver fat content at 2 weeks minus liver fat content at baseline. Lower values indicate lower liver fat content and may reflect improvement in hepatic steatosis.

Show more lines
Baseline and end of each 2-week dietary intervention period

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Change in Gut Microbiome Alpha Diversity After 2 Weeks of LGI and HGI Diets
Aikaikkuna: Baseline and end of each 2-week dietary intervention period

Change in gut microbiome alpha diversity from baseline to the end of each 2-week dietary intervention period (LGI diet and HGI diet), assessed by 16S rRNA gene sequencing in participants with NAFLD. Higher values indicate greater microbial alpha diversity. Values represent the change from baseline to the end of the intervention period.
Baseline and end of each 2-week dietary intervention period
Change in Gut Microbiome Beta Diversity From Baseline to End of Each 2-Week Dietary Intervention
Aikaikkuna: Baseline and end of each 2-week dietary intervention period

Change in gut microbiome beta diversity from baseline to the end of each 2-week dietary intervention period (LGI diet and HGI diet), assessed by 16S rRNA gene sequencing using UniFrac distance. Beta diversity measures differences in microbial community composition between samples. Lower UniFrac distance values indicate greater similarity between microbial communities, whereas higher values indicate greater dissimilarity. UniFrac distance ranges from 0 to 1, where 0 indicates identical communities and 1 indicates completely distinct communities. Values represent the change from baseline to the end of each intervention period.
Baseline and end of each 2-week dietary intervention period
Change in Blood Glucose Level From Baseline to End of 2-Week Dietary Intervention
Aikaikkuna: Baseline and end of each 2-week dietary intervention period

Change in fasting blood glucose concentration from baseline to the end of each 2-week dietary intervention period (LGI diet and HGI diet), measured using a Horiba automated analyser. Values represent blood glucose at 2 weeks minus blood glucose at baseline. Higher values indicate an increase in blood glucose concentration, whereas lower or negative values indicate a decrease in blood glucose concentration.
Baseline and end of each 2-week dietary intervention period
Blood Insulin Change in Fasting Insulin Concentration From Baseline to End of Each 2-Week Dietary Intervention
Aikaikkuna: Baseline and end of each 2-week dietary intervention period

Change in fasting insulin concentration from baseline to the end of each 2-week dietary intervention period (LGI diet and HGI diet). Values represent insulin concentration at 2 weeks minus insulin concentration at baseline. Lower values indicate lower circulating insulin concentrations.
Baseline and end of each 2-week dietary intervention period
Change in Liver Function Biomarkers From Baseline to End of Each 2-Week Dietary Intervention
Aikaikkuna: 2 Baseline and end of each 2-week dietary intervention period Show more lines

Change in liver function biomarkers from baseline to the end of each 2-week dietary intervention period. Values represent the biomarker concentration at 2 weeks minus the concentration at baseline The blood liver function tests (LFTs) to be assessed are GGT(Gamma-Glutamyl Transferase), ALP(Alkaline Phosphatase), AST(Aspartate Amino Transferase), and ALT(Alanine Amino Transferase)
2 Baseline and end of each 2-week dietary intervention period Show more lines
Change in Blood Lipids Concentration From Baseline to End of Each 2-Week Dietary Intervention Show More Lines
Aikaikkuna: Baseline and end of each 2-week dietary intervention period

Change in fasting blood lipids concentration from baseline to the end of each 2-week dietary intervention period. Values represent triglyceride concentration at 2 weeks minus triglyceride concentration at baseline. The blood lipids biomarkers to be assessed are Total Cholesterol, High-density lipoprotein, low-density lipoprotein, Triglycerides.
Baseline and end of each 2-week dietary intervention period
Change in Gut Hormones Concentration From Baseline to End of Each 2-Week Dietary Intervention
Aikaikkuna: Baseline and end of each 2-week dietary intervention period

Change in gut hormones concentration from baseline to the end of each 2-week dietary intervention period. Values represent GLP-1 concentration at 2 weeks minus GLP-1 concentration at baseline.using radioimmunoassay (RIA) or Sandwich ELISA methods. The blood gut hormones to be assessed were Leptin, Ghrelin,, GLP-1 (Glucagon-like peptide 1).
Baseline and end of each 2-week dietary intervention period
Change in Plasma Short-Chain Fatty Acid Concentrations From Baseline to End of Each 2-Week Dietary Intervention
Aikaikkuna: Baseline and end of each 2-week dietary intervention period

Change in plasma short-chain fatty acid (SCFA) concentrations from baseline to the end of each 2-week dietary intervention period (LGI diet and HGI diet) in participants with NAFLD. Plasma SCFAs (including acetic acid, butyric acid, and valeric acid) were measured in fasting blood samples. Values represent the concentration at the end of the intervention period minus the concentration at baseline. Higher values indicate higher circulating SCFA concentrations.
Baseline and end of each 2-week dietary intervention period
Change in Body Weight From Baseline to End of Each 2-Week Dietary Intervention
Aikaikkuna: Baseline and end of each 2-week dietary intervention period

Change in body weight from baseline to the end of each 2-week dietary intervention period (LGI diet and HGI diet) in participants with NAFLD. Body weight was measured in kilograms using calibrated scales. Values represent body weight at the end of the intervention period minus body weight at baseline. Negative values indicate weight loss, whereas positive values indicate weight gain.
Baseline and end of each 2-week dietary intervention period
Change in Composite Appetite Sensations (CAS) Score From Baseline to End of Each 2-Week Dietary Intervention
Aikaikkuna: Baseline and end of each 2-week dietary intervention period

Composite Appetite Sensations (CAS) score was derived from Visual Analogue Scale (VAS) assessments of appetite. Participants rated hunger, satisfaction, fullness, desire to eat, and prospective food consumption on 10-cm (0-100 mm) visual analogue scales. The CAS score was calculated as:

2

3 [Hunger + (100 - Satisfaction) + (100 - Fullness) + Desire to Eat + Prospective Food Consumption] / 5 4

5 CAS scores range from 0 to 100 mm, with higher scores indicating greater overall appetite and lower scores indicating lower appetite. Values represent the change from baseline to the end of each 2-week dietary intervention period.
Baseline and end of each 2-week dietary intervention period

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

University of Nottingham

Tutkijat

  • Päätutkija: Guru Aithal, PhD, University of Nottingham

Julkaisuja ja hyödyllisiä linkkejä

Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.

Yleiset julkaisut

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Torstai 10. joulukuuta 2020

Ensisijainen valmistuminen (Todellinen)

Tiistai 18. lokakuuta 2022

Opintojen valmistuminen (Todellinen)

Tiistai 18. lokakuuta 2022

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Maanantai 20. huhtikuuta 2020

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Perjantai 29. toukokuuta 2020

Ensimmäinen Lähetetty (Todellinen)

Torstai 4. kesäkuuta 2020

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Maanantai 5. lokakuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Maanantai 13. heinäkuuta 2026

Viimeksi vahvistettu

Torstai 1. joulukuuta 2022

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Muita asiaankuuluvia MeSH-ehtoja

Muut tutkimustunnusnumerot

  • 19042
  • 262245 (Muu tunniste: IRAS)
  • 19/EM/0291 (Muu tunniste: REC)

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

JOO

IPD-suunnitelman kuvaus

Within a five-year timeframe, the final anonymized trial data will be uploaded to the https://rdmc.nottingham.ac.uk public repository after consistency and quality have been verified by the project team and publication of the results. Data from this trial are intended to be presented at local and international conferences including those attended by clinicians and dietitians and will also be used as part of a Philosophy Doctorate thesis. Publications will be in peer reviewed journals. No participant will be identified in any of these publications.

IPD-jaon aikakehys

within five years time-frame

IPD-jaon käyttöoikeuskriteerit

Public repository. presented at local and international conferences. part of a Philosophy Doctorate thesis

IPD-jakamista tukeva tietotyyppi

  • STUDY_PROTOCOL
  • MAHLA
  • ICF

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa